Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON48488
NL-OMON48488
Recruiting
Not Applicable

Effect of androgen deprivation therapy on uptake of PSMA ligand in patients with salivary duct carcinoma: an explorative study. - ADT-SCA

Radboud Universitair Medisch Centrum0 sites14 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Radboud Universitair Medisch Centrum
Enrollment
14
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients must have the ability to provide written informed consent.
  • •Patients must be \>\= 18 years of age.
  • •Patients must have histological, pathological, and/or cytological
  • •confirmation of salivary duct carcinoma, androgen receptor positive.
  • •Only patients with locally advanced, recurrent or metastatic salivary duct
  • •carcinoma can participate.
  • •Patients must have at least one lesion with a diameter of \>\= 1\.5 cm.
  • •Patients whom intend to start androgen deprivation therapy, after this has
  • •been re\-commended by the treating physician as standard treatment.

Exclusion Criteria

  • •Contra\-indication for PET imaging: pregnancy or breast feeding or severe
  • •claustrophobia
  • •Impaired renal function: MDRD \<30 ml/min/1,73 m2
  • •Impaired liver function: AST and ALT ALT \>\= 2\.5 x ULN (\>\=5 x ULN for patients
  • •with liver metastases)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigeMetastatic prostate cancerMedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-004853-26-FITurku University Hospital35
Active, not recruiting
Phase 1
The effect of androgen deprivation therapy on prostate specific membrane antigen (PSMA)
EUCTR2017-002345-29-FITurku University Hospital5
Recruiting
Not Applicable
To determine whether androgen deprivation therapy or androgen blockage therapy upregulates receptor activity of Gallium68 Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans for men with castrate resistant prostate cancer.
ACTRN12617001116314St Vincent's Hospital, Sydney20
Not yet recruiting
Phase 3
Effect of systematic lifestyle advice & use of cholesterol reducing drugs on cardiovascular disease outcomes among men with newly diagnosed prostate cancer on androgen deprivation therapy.Health Condition 1: C61- Malignant neoplasm of prostate
CTRI/2023/07/054807Dr Jehonathan Pinthus Dr Leong Darryl
Active, not recruiting
Phase 4
The effect of intermittent versus continuous androgen deprivation therapy in Chinese patients with advanced prostate cancer: A prospective controlled Trial from Chinaprostate cancerCancer - Prostate
ACTRN12613000107729Changhai Hospital, Second Military Medical University100